Rocket Pharmaceuticals, Inc. Other Depreciation and Amortization
Rocket Pharmaceuticals, Inc. (RCKT) reported Other Depreciation and Amortization of $3.17 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherDepreciationAndAmortization · last filed 2026-08-10
- Rocket Pharmaceuticals, Inc. other depreciation and amortization for the quarter ending 2026-06-30 was $1.56M, a 23.33% decline year-over-year.
- Rocket Pharmaceuticals, Inc. other depreciation and amortization for the quarter ending 2026-03-31 was $1.61M, a 34.39% decline year-over-year.
- Rocket Pharmaceuticals, Inc. other depreciation and amortization for the quarter ending 2025-12-31 was $1.68M, a 7.90% decline year-over-year.
- Rocket Pharmaceuticals, Inc. other depreciation and amortization for the quarter ending 2025-09-30 was $2.70M, a 45.98% increase year-over-year.
- Rocket Pharmaceuticals, Inc. other depreciation and amortization for fiscal 2025 was $8.87M, a 22.85% increase from fiscal 2024.
- Rocket Pharmaceuticals, Inc. other depreciation and amortization for fiscal 2024 was $7.22M, a 46.06% increase from fiscal 2023.
- Rocket Pharmaceuticals, Inc. other depreciation and amortization for fiscal 2023 was $4.94M, a 25.74% increase from fiscal 2022.
- Rocket Pharmaceuticals, Inc. other depreciation and amortization for fiscal 2022 was $3.93M, a 21.36% increase from fiscal 2021.
| Period end | Other Depreciation and Amortization 3 month | Other Depreciation and Amortization 6 month | Other Depreciation and Amortization 9 month | Other Depreciation and Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $3.17M 10-Q · filed 2026-08-10 | $4.85M derived: sum of 3 quarters · filed 2026-08-10 | $7.55M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $1.61M 10-Q · filed 2026-05-07 | $3.29M derived: sum of 2 quarters · filed 2026-05-07 | $5.99M derived: sum of 3 quarters · filed 2026-05-07 | $8.03M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.38M derived: sum of 2 quarters · filed 2026-02-26 | $6.42M derived: sum of 3 quarters · filed 2026-08-10 | $8.87M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.74M derived: sum of 2 quarters · filed 2026-08-10 | $7.19M 10-Q · filed 2025-11-06 | $9.02M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $2.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $4.49M 10-Q · filed 2026-08-10 | $6.31M derived: sum of 3 quarters · filed 2026-08-10 | $8.16M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $2.45M 10-Q · filed 2026-05-07 | $4.27M derived: sum of 2 quarters · filed 2026-05-07 | $6.12M derived: sum of 3 quarters · filed 2026-05-07 | $7.96M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.67M derived: sum of 2 quarters · filed 2026-02-26 | $5.50M derived: sum of 3 quarters · filed 2026-02-26 | $7.22M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.68M derived: sum of 2 quarters · filed 2025-11-06 | $5.40M 10-Q · filed 2025-11-06 | $6.79M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $3.55M 10-Q · filed 2025-08-07 | $4.94M derived: sum of 3 quarters · filed 2025-08-07 | $6.17M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.72M 10-Q · filed 2025-05-08 | $3.11M derived: sum of 2 quarters · filed 2025-05-08 | $4.33M derived: sum of 3 quarters · filed 2025-05-08 | $5.53M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.62M derived: sum of 2 quarters · filed 2025-02-27 | $3.81M derived: sum of 3 quarters · filed 2025-02-27 | $4.94M 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.41M derived: sum of 2 quarters · filed 2024-11-07 | $3.55M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $2.33M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $1.14M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $3.93M 10-K · filed 2025-02-27 | |||
| 2022-06-30 | $1.00M 10-Q · filed 2022-08-09 | $1.80M 10-Q · filed 2022-08-09 | ||
| 2022-03-31 | $767.00K 10-Q · filed 2022-05-06 | |||
| 2021-12-31 | $3.24M 10-K · filed 2024-02-27 | |||
| 2021-06-30 | $700.00K 10-Q · filed 2022-08-09 | $1.38M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $674.00K 10-Q · filed 2022-05-06 | |||
| 2020-12-31 | $1.15M 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $426.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |